Quantitative determination of ginsenoside Rh2 in rat biosamples by liquid chromatography electrospray ionization mass spectrometry
- 3 November 2006
- journal article
- research article
- Published by Springer Nature in Analytical and Bioanalytical Chemistry
- Vol. 386 (7-8) , 2043-2053
Abstract
Ginsenoside Rh2 is a “hot” natural compound with great potential as a new anti-cancer drug based on abundant pharmacological experiments. However, no systemic pharmacokinetic study of Rh2 was reported because current analysis methods could not fully meet the requirements. Thus, we developed a simple LC/MS method with highly improved sensitivities for the determination of Rh2 in rat plasma, bile, urine, feces and most tissues. The tissues and feces were firstly homogenized mechanically using buffer and methanol as the media, respectively. Plasma, bile, urine and tissue homogenates were extracted with diethyl ether for sample preparation. Feces homogenates were directly deproteinized with acetonitrile. The subsequent analysis procedures were performed on a Shimadzu LCMS2010A system (electrospray ionization single quadrupole mass analyzer), with an ODS column (150 mm × 2.0-mm i.d., 5 μm) plus a C18 guard column for separation and ammonium chloride (500 μmol) as mobile phase additive. The proportions of mobile phase were changed timely according to gradient programs. Chlorinated adducts of molecular ions [M + Cl]− of Rh2 at m/z 657.35 and internal standard digitoxin at m/z 799.55 were monitored in selective ion monitoring mode of negative ions. The method was validated to be accurate, precise and rugged with good linearity in all matrices, according to the FDA guidelines. The lower limits of quantitation in rat plasma, urine and feces were 0.2, 0.2 and 20 ng/mL respectively. Stability studies were also performed, indicating that there were no stability-related problems in the analytical procedure of Rh2. The proposed method was successfully applied to the preclinical pharmacokinetic research of Rh2 in rats, including plasma kinetics, tissue distribution and excretion studies.Keywords
This publication has 22 references indexed in Scilit:
- INCREASE OF INSULIN SECRETION BY GINSENOSIDE RH2 TO LOWER PLASMA GLUCOSE IN WISTAR RATSClinical and Experimental Pharmacology and Physiology, 2006
- Liquid chromatography/mass spectrometric analysis of rat samples for in vivo metabolism and pharmacokinetic studies of ginsenoside Rh2Rapid Communications in Mass Spectrometry, 2005
- Simultaneous rapid quantification of ginsenoside Rg1 and its secondary glycoside Rh1 and aglycone protopanaxatriol in rat plasma by liquid chromatography–mass spectrometry after solid-phase extractionJournal of Pharmaceutical and Biomedical Analysis, 2005
- High performance liquid chromatographic–mass spectrometric determination of ginsenoside Rg3 and its metabolites in rat plasma using solid-phase extraction for pharmacokinetic studiesJournal of Chromatography B, 2005
- Liquid chromatography/tandem mass spectrometry for pharmacokinetic studies of 20( R )‐ginsenoside Rg3 in dogRapid Communications in Mass Spectrometry, 2005
- Analysis methods of ginsenosidesJournal of Chromatography B, 2004
- Liquid chromatography–electrospray ionization mass spectrometry for metabolism and pharmacokinetic studies of ginsenoside Rg3Analytica Chimica Acta, 2003
- Anticarcinogenic Effect and Enhancement of Metastatic Potential of BALB/c 3T3 Cells by Ginsenoside Rh2Japanese Journal of Cancer Research, 2001
- Inhibitory Effects of Ginsenoside Rh2 on Tumor Growth in Nude Mice Bearing Human Ovarian Cancer CellsJapanese Journal of Cancer Research, 1998
- In vitro induction of differentiation by ginsenosides in F9 teratocarcinoma cellsEuropean Journal of Cancer, 1996